Pfizer (PFE), BioNTech SE (BNTX) Report Agreement with the U.K. for 30M Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/20/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to Pfizer (PFE), BioNTech SE (BNTX) Report Agreement with the U.K. for 30M Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2

Morgan Stanley Reiterates Equalweight Rating on Pfizer (PFE) Following COVID Vaccine Update

July 21, 2020 8:42 AM EDT

Morgan Stanley analyst David Risinger reiterated an Equalweight rating and $36.00 price target on Pfizer (NYSE: PFE) following the company's COVID vaccine update. Results appear encouraging vs. MRNA and AZN, but x-trial comps are confounded.

Risinger await results from BNT162b2(full spike)... More

Mizuho 'Encouraged' by Pfizer (PFE) COVID-19 Vaccine Data

July 20, 2020 10:57 AM EDT

Mizuho Securities analyst Vamil Divan reiterated a Buy rating and $38.00 price target on Pfizer (NYSE: PFE), citing continued positive progress on its COVID vaccine.

The analyst commented, "We are encouraged by new data from Pfizer and partner BioNTech on the progress they are... More

Exclusive: EU in talks with Moderna, BioNtech, CureVac to secure possible COVID vaccines

July 17, 2020 7:29 AM EDT

By Francesco Guarascio

BRUSSELS (Reuters) - The European Union is negotiating advance purchase deals of potential COVID-19 vaccines with drugmakers Moderna (NASDAQ: MRNA), Sanofi and Johnson & Johnson (NYSE: JNJ) as well as biotech firms BioNtech (NASDAQ: BNTX) and CureVac, two EU sources told Reuters.

The talks follow a deal reached in June by four EU member states with AstraZeneca (NYSE: AZN) for the upfront purchase of 400 million doses of its potential COVID-19 vaccine, in... More